Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies, 54474-54476 [2024-14411]
Download as PDF
<![CDATA[
54474
Federal Register / Vol. 89, No. 126 / Monday, July 1, 2024 / Notices
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 25, 2024.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–14423 Filed 6–28–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, Cancer
Diagnosis and Treatment (CDT), July 17,
2024, 09:00 a.m. to July 18, 2024, 07:30
p.m., National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, which was
published in the Federal Register on
June 25, 2024, 89 FR 53113, FR Doc
2024–13839.
This meeting is being amended to
change the meeting panel name from
Cancer Diagnosis and Treatment (CDT)
to Small Business: Cancer Diagnosis and
Treatment (CDT). The meeting is closed
to the public.
Dated: June 25, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–14369 Filed 6–28–24; 8:45 am]
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Research Education
Program Advancing the Careers of a Diverse
Research Workforce (R25 Clinical Trial Not
Allowed).
Date: July 29, 2024.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G48,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Soheyla Saadi, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G48, Rockville, MD
20892, 301–435–0903, saadisoh@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: June 25, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–14390 Filed 6–28–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
ddrumheller on DSK120RN23PROD with NOTICES1
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
20:36 Jun 28, 2024
Jkt 262001
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIH Support for
Conferences and Scientific Meetings (Parent
R13 Clinical Trial Not Allowed).
Date: July 29–31, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Dated: June 25, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–14391 Filed 6–28–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
National Institutes of Health
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health, 5601 Fishers Lane, MSC 9834,
Rockville, MD 20852 (Video Assisted
Meeting).
Contact Person: Rekha Dhanwani, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, MSC 9834, Rockville, MD
20852, (240) 627–3076, rekha.dhanwani@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines) using
Urine and the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
FOR FURTHER INFORMATION CONTACT:
Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Flanagan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) publishes a notice
listing all HHS-certified laboratories and
Instrumented Initial Testing Facilities
(IITFs) in the Federal Register during
the first week of each month, in
accordance with Section 9.19 of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
SUMMARY:
E:\FR\FM\01JYN1.SGM
01JYN1
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 126 / Monday, July 1, 2024 / Notices
Section 9.17 of the Mandatory
Guidelines using Oral Fluid. If any
laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/drug-testing-resources/
certified-lab-list.
HHS separately notifies Federal
agencies of the laboratories and IITFs
currently certified to meet the standards
of the Mandatory Guidelines using
Urine and of the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); January 23,
2017 (82 FR 7920); and on October 12,
2023 (88 FR 70768).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020, and subsequently
revised in the Federal Register on
October 12, 2023 (88 FR 70814).
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
allowing for oral fluid drug testing have
been published. The Mandatory
Guidelines require strict standards that
laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on specimens for Federal
agencies. HHS does not allow IITFs to
conduct oral fluid testing.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
VerDate Sep<11>2014
20:36 Jun 28, 2024
Jkt 262001
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines using Urine and/
or Oral Fluid. An HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that the test facility has met minimum
standards. HHS does not allow IITFs to
conduct oral fluid testing.
HHS-Certified Laboratories Approved
to Conduct Oral Fluid Drug Testing
In accordance with the Mandatory
Guidelines using Oral Fluid effective
October 10, 2023 (88 FR 70814), the
following HHS-certified laboratories
meet the minimum standards to conduct
drug and specimen validity tests on oral
fluid specimens:
At this time, there are no laboratories
certified to conduct drug and specimen
validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial
Testing Facilities Approved to Conduct
Urine Drug Testing:
In accordance with the Mandatory
Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the
following HHS-certified IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Dynacare*, 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7, 780–
784–1190, (Formerly: GammaDynacare Medical Laboratories)
HHS-Certified Laboratories Approved
to Conduct Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the
following HHS-certified laboratories
meet the minimum standards to conduct
drug and specimen validity tests on
urine specimens:
Alere Toxicology Services, 1111 Newton
St. Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917
Desert Tox, LLC, 5425 E Bell Rd, Suite
125, Scottsdale, AZ, 85254, 602–457–
5411/623–748–5045
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
54475
Dynacare*, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630, (Formerly: GammaDynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845,
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
Laboratory Corporation of America,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295,
(Formerly: Legacy Laboratory Services
Toxicology MetroLab)
Laboratory Corporation of America
Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984,
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group)
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339, (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center)
MedTox Laboratories, Inc., 402 W
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088. Testing for Veterans Affairs
(VA) Employees Only
Omega Laboratories, Inc.,* 2150
Dunwin Drive, Unit 1 & 2,
Mississauga, ON, Canada L5L 5M8,
289–919–3188
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942, (Formerly: Centinela
Hospital Airport Toxicology
Laboratory)
Phamatech, Inc., 15175 Innovation
Drive, San Diego, CA 92128, 888–
635–5840
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
E:\FR\FM\01JYN1.SGM
01JYN1
54476
Federal Register / Vol. 89, No. 126 / Monday, July 1, 2024 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
610–631–4600/877–642–2216,
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085, Testing for
Department of Defense (DoD)
Employees Only
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories continued under
DOT authority. The responsibility for
conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory as meeting
the minimum standards of the current
Mandatory Guidelines published in the
Federal Register. After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program. DOT established this process
in July 1996 (61 FR 37015) to allow
foreign laboratories to participate in the
DOT drug testing program.
Anastasia D. Flanagan,
Public Health Advisor, Division of Workplace
Programs.
[FR Doc. 2024–14411 Filed 6–28–24; 8:45 am]
BILLING CODE 4160–20–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Accreditation and Approval of
AmSpec, LLC (Belle Chasse, LA) as a
Commercial Gauger and Laboratory
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of accreditation and
approval of AmSpec, LLC (Belle Chasse,
LA) as a commercial gauger and
laboratory.
AGENCY:
Notice is hereby given,
pursuant to CBP regulations, that
AmSpec, LLC (Belle Chasse, LA), has
been approved to gauge petroleum and
certain petroleum products and
accredited to test petroleum and certain
petroleum products for customs
purposes for the next three years as of
May 11, 2023.
DATES: AmSpec, LLC (Belle Chasse, LA)
was approved and accredited as a
commercial gauger and laboratory as of
May 11, 2023. The next inspection date
will be scheduled for May 2026.
SUMMARY:
Dr.
Eugene Bondoc, Laboratories and
Scientific Services Directorate, U.S.
Customs and Border Protection, 1300
Pennsylvania Avenue NW, Suite 1501–
A North, Washington, DC 20229, tel.
202–344–1060.
FOR FURTHER INFORMATION CONTACT:
Notice is
hereby given pursuant to 19 CFR 151.12
and 19 CFR 151.13, that AmSpec, LLC,
9221 Highway 13, Belle Chasse, LA
70037, has been approved to gauge
petroleum and certain petroleum
products and accredited to test
petroleum and certain petroleum
products for customs purposes, in
accordance with the provisions of 19
CFR 151.12 and 19 CFR 151.13 as of
May 11, 2023.
AmSpec, LLC (Belle Chasse, LA) is
approved for the following gauging
procedures for petroleum and certain
petroleum products from the American
Petroleum Institute (API):
SUPPLEMENTARY INFORMATION:
API
chapters
3 ...............
7 ...............
8 ...............
12 .............
17 .............
Title
Tank Gauging.
Temperature Determination.
Sampling.
Calculations.
Maritime Measurement.
AmSpec, LLC (Belle Chasse, LA) is
accredited for the following laboratory
analysis procedures and methods for
petroleum and certain petroleum
products set forth by the U.S. Customs
and Border Protection Laboratory
Methods (CBPL) and American Society
for Testing and Materials (ASTM):
CBPL No.
ASTM
Title
27–02 .................
D 1298 .....
27–04
27–06
27–08
27–11
D
D
D
D
Standard Test Method for Density, Relative Density (Specific Gravity), or API Gravity of Crude Petroleum and
Liquid Petroleum Products by Hydrometer Method.
Standard Test Method for Water in Petroleum Products and Bituminous Materials by Distillation.
Standard Test Method for Sediment in Crude Oils and Fuel Oils by the Extraction Method.
Standard Test Method for Distillation of Petroleum Products at Atmospheric Pressure.
Standard Test Method for Kinematic Viscosity of Transparent and Opaque Liquids (and Calculation of Dynamic
Viscosity).
Standard Test Method for Sulfur in Petroleum and Petroleum Products by Energy Dispersive X-ray Fluorescence Spectrometry.
Standard Test Method for Density, Relative Density, and API Gravity of Liquids by Digital Density Meter.
Standard Test Method for Density and Relative Density of Liquids by Digital Density Meter.
Standard Test Method for Water and Sediment in Middle Distillate Fuels by Centrifuge.
Standard Test Method For Vapor Pressure of Petroleum Products (Mini Method).
.................
.................
.................
.................
95 .........
473 .......
86 .........
445 .......
27–13 .................
D 4294 .....
27–14
27–48
27–53
27–58
D
D
D
D
.................
.................
.................
.................
2622
4052
2709
5191
.....
.....
.....
.....
Anyone wishing to employ this entity
to conduct laboratory analyses and
gauger services should request and
receive written assurances from the
entity that it is accredited or approved
by the U.S. Customs and Border
Protection to conduct the specific test or
gauger service requested. Alternatively,
inquiries regarding the specific test or
VerDate Sep<11>2014
20:36 Jun 28, 2024
Jkt 262001
gauger service this entity is accredited
or approved to perform may be directed
to the U.S. Customs and Border
Protection by calling (202) 344–1060.
The inquiry may also be sent to
CBPGaugersLabs@cbp.dhs.gov. Please
reference the website listed below for a
complete listing of CBP approved
gaugers and accredited laboratories.
PO 00000
Frm 00073
Fmt 4703
Sfmt 9990
https://www.cbp.gov/about/labsscientific/commercial-gaugers-andlaboratories.
James D. Sweet,
Laboratory Director, Houston, Laboratories
and Scientific Services Directorate.
[FR Doc. 2024–14360 Filed 6–28–24; 8:45 am]
BILLING CODE 9111–14–P
E:\FR\FM\01JYN1.SGM
01JYN1
]]>Agencies
[Federal Register Volume 89, Number 126 (Monday, July 1, 2024)]
[Notices]
[Pages 54474-54476]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-14411]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of HHS-Certified Laboratories and Instrumented
Initial Testing Facilities Which Meet Minimum Standards To Engage in
Urine and Oral Fluid Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories and Instrumented Initial Testing
Facilities (IITFs) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and the laboratories currently
certified to meet the standards of the Mandatory Guidelines using Oral
Fluid.
FOR FURTHER INFORMATION CONTACT: Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240-276-2600 (voice);
[email protected] (email).
SUPPLEMENTARY INFORMATION: The Department of Health and Human Services
(HHS) publishes a notice listing all HHS-certified laboratories and
Instrumented Initial Testing Facilities (IITFs) in the Federal Register
during the first week of each month, in accordance with Section 9.19 of
the Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
[[Page 54475]]
Section 9.17 of the Mandatory Guidelines using Oral Fluid. If any
laboratory or IITF certification is suspended or revoked, the
laboratory or IITF will be omitted from subsequent lists until such
time as it is restored to full certification under the Mandatory
Guidelines.
If any laboratory or IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the internet at https://www.samhsa.gov/workplace/drug-testing-resources/certified-lab-list.
HHS separately notifies Federal agencies of the laboratories and
IITFs currently certified to meet the standards of the Mandatory
Guidelines using Urine and of the laboratories currently certified to
meet the standards of the Mandatory Guidelines using Oral Fluid.
The Mandatory Guidelines using Urine were first published in the
Federal Register on April 11, 1988 (53 FR 11970), and subsequently
revised in the Federal Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); January 23, 2017 (82 FR 7920); and on October
12, 2023 (88 FR 70768).
The Mandatory Guidelines using Oral Fluid were first published in
the Federal Register on October 25, 2019 (84 FR 57554) with an
effective date of January 1, 2020, and subsequently revised in the
Federal Register on October 12, 2023 (88 FR 70814).
The Mandatory Guidelines were initially developed in accordance
with Executive Order 12564 and section 503 of Public Law 100-71 and
allowed urine drug testing only. The Mandatory Guidelines using Urine
have since been revised, and new Mandatory Guidelines allowing for oral
fluid drug testing have been published. The Mandatory Guidelines
require strict standards that laboratories and IITFs must meet in order
to conduct drug and specimen validity tests on specimens for Federal
agencies. HHS does not allow IITFs to conduct oral fluid testing.
To become certified, an applicant laboratory or IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a laboratory or IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and IITFs in the applicant stage of certification are
not to be considered as meeting the minimum requirements described in
the HHS Mandatory Guidelines using Urine and/or Oral Fluid. An HHS-
certified laboratory or IITF must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA), which attests that the test facility
has met minimum standards. HHS does not allow IITFs to conduct oral
fluid testing.
HHS-Certified Laboratories Approved to Conduct Oral Fluid Drug Testing
In accordance with the Mandatory Guidelines using Oral Fluid
effective October 10, 2023 (88 FR 70814), the following HHS-certified
laboratories meet the minimum standards to conduct drug and specimen
validity tests on oral fluid specimens:
At this time, there are no laboratories certified to conduct drug
and specimen validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial Testing Facilities Approved to
Conduct Urine Drug Testing:
In accordance with the Mandatory Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the following HHS-certified IITFs meet
the minimum standards to conduct drug and specimen validity tests on
urine specimens:
Dynacare*, 6628 50th Street NW, Edmonton, AB Canada T6B 2N7, 780-784-
1190, (Formerly: Gamma-Dynacare Medical Laboratories)
HHS-Certified Laboratories Approved to Conduct Urine Drug Testing
In accordance with the Mandatory Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the following HHS-certified
laboratories meet the minimum standards to conduct drug and specimen
validity tests on urine specimens:
Alere Toxicology Services, 1111 Newton St. Gretna, LA 70053, 504-361-
8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS
66215-2802, 800-445-6917
Desert Tox, LLC, 5425 E Bell Rd, Suite 125, Scottsdale, AZ, 85254, 602-
457-5411/623-748-5045
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890
Dynacare*, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679-
1630, (Formerly: Gamma-Dynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
Laboratory Corporation of America, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295, (Formerly: Legacy Laboratory Services
Toxicology MetroLab)
Laboratory Corporation of America Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
MedTox Laboratories, Inc., 402 W County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
Testing for Veterans Affairs (VA) Employees Only
Omega Laboratories, Inc.,* 2150 Dunwin Drive, Unit 1 & 2, Mississauga,
ON, Canada L5L 5M8, 289-919-3188
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888-635-
5840
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403,
[[Page 54476]]
610-631-4600/877-642-2216, (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories)
US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085, Testing for
Department of Defense (DoD) Employees Only
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories continued under DOT authority.
The responsibility for conducting quarterly performance testing plus
periodic on-site inspections of those LAPSA-accredited laboratories was
transferred to the U.S. HHS, with the HHS' NLCP contractor continuing
to have an active role in the performance testing and laboratory
inspection processes. Other Canadian laboratories wishing to be
considered for the NLCP may apply directly to the NLCP contractor just
as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory as meeting the minimum
standards of the current Mandatory Guidelines published in the Federal
Register. After receiving DOT certification, the laboratory will be
included in the monthly list of HHS-certified laboratories and
participate in the NLCP certification maintenance program. DOT
established this process in July 1996 (61 FR 37015) to allow foreign
laboratories to participate in the DOT drug testing program.
Anastasia D. Flanagan,
Public Health Advisor, Division of Workplace Programs.
[FR Doc. 2024-14411 Filed 6-28-24; 8:45 am]
BILLING CODE 4160-20-P
